MediGene AG was to announce today that it has formed a worldwide alliance to develop its Viral Vaccine with Schering AG for the treatment of precancerous cervica

MediGene (Munich, Germany) is using protein fusion technology to develop a chimeric viral-like particle (CVLP) capsid designed both to vaccinate against HPV infection and to treat HPV infected patients. The CVLP is created by an HPV-L1E7 fusion protein, which self-assembles into virus-like particles able to cause a pseudo-infection. The L1 structural protein from the protein case of HPV induces neutralizing antibodies, while the shortened E7 regulatory protein, which HPV uses to replicate, causes a cytotoxic T cell response.